ArticlePloS one2020

Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.

Ayano Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.